FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

SPOTLIGHT: Daiichi Sankyo buys OTC business


Daiichi Sankyo has inked a deal to buy the OTC unit of Astellas--Zepharma--for 20 billion yen. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:

More stories about OTC drugs   Astellas Pharma   Daiichi Sankyo   Biotech deals